Chronic Obstructive Pulmonary Disease Pipeline Landscape Analysis: 70+ Key Players & 70+ Pipeline Drugs

DelveInsight's, "Chronic Obstructive Pulmonary Disease Pipeline Insight, 2022," report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the pipeline drug profiles, including Chronic Obstructive Pulmonary Disease clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Chronic Obstructive Pulmonary Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Obstructive Pulmonary Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report

DelveInsight's Chronic Obstructive Pulmonary Disease Pipeline analysis depicts a robust space with 70+ active players working to develop 70+ pipeline treatment therapies.
The leading Chronic Obstructive Pulmonary Disease Companies are working such as GlaxoSmithKline, Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, AstraZeneca, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., CSL Behring; Grifols Biologicals, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, and others.
Promising Chronic Obstructive Pulmonary Disease Pipeline therapies such as TD-4208, Tiotr, Itepekimab (SAR440340), Reldesemtiv, Formoterol, Roflumilast, Benralizumab, MV130, SB-240563, SAR440340, CHF 6001, YPL 001, and others.
The Chronic Obstructive Pulmonary Disease Companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.


Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Pipeline Report

Benralizumab (FASENRA) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophil and attracts natural killer cells to induce rapid and near-complete depletion of eosinophil via apoptosis (programmed cell death). The drug is approved by the US FDA for asthma and is currently being developed for other respiratory and immunological disorders such as COPD, atopic dermatitis, and others. The drug was earlier in GALATHEA and TERRANOVA trials (randomized, double-blinded, placebo-controlled, parallel-group trials that assessed the safety and efficacy of Fasenra 30mg and 100mg for preventing COPD exacerbations). At present, the drug is in RESOLUTE (Phase III trial) to evaluate its efficacy and safety.
MV130 (BACTEK) is a bacterial mucosal vaccine or a bacterial polyvalent vaccine in a spray that is administered sublingually to treat recurrent respiratory tract infections in children and adults. MV130 plays a relevant role in modulating the functional activity of the innate and adaptive immune response by stimulating dendritic cells, which are part of innate immunity. A Phase III clinical trial is evaluating MV130 in patients with COPD. At present, the trial is ongoing in Spain.
SB-240563 (mepolizumab) is a humanized monoclonal antibody that blocks human interleukin 5 (hIL-5) from binding to its receptor. Initial clinical studies investigated the safety and efficacy of SB-240563 for the treatment of asthma and atopic dermatitis (AD). SB-240563 reduced peripheral and tissue eosinophils in patients with asthma and healthy volunteers. Currently, it is in the Phase III stage of the clinical trials.
SAR440340 (Itepekimab) is a humanized IgG4P monoclonal antibody that blocks human interleukin 33 (hIL-33) from binding to its receptor. IL-33 is an epithelial cytokine that initiates and amplifies innate and adaptive type 2 and 1 inflammatory pathways in response to epithelial insults due to exposure to allergens, viruses, cigarette smoke, and pollutants. SAR440340 was invented using Regeneron's proprietary VelocImmune technology that yields optimized fully-human antibodies and is being developed jointly by Regeneron and Sanofi as part of a global collaboration agreement.
CHF6001 is a novel inhaled phosphodiesterase-4 (PDE-4) inhibitor developed as an extrafine formulation (i.e., with mass median aerodynamic diameter  ≤ 2 μm) and low systemic exposure. This allows CHF6001 to reach a therapeutic concentration in the target organ, the lung, with reduced systemic exposure, limiting systemic adverse effects. The drug is administered through a dry powder inhaler (DPI NEXThaler).
YPL 001 is a drug molecule that belongs to the anti-inflammatory and anti-histamine class of drugs. The drug is being developed for COPD. YPL-001 is a product developed using wild chives, which grow naturally in nature, as a raw material. A Phase II trial was conducted in US hospitals to assess the drug's safety in patients with moderate-to-severe COPD. In Phase I studies, YPL-001 was well tolerated in healthy subjects following single (up to 320 mg) and multiple (up to 240 mg twice daily [BID]) oral doses with no serious adverse events (AEs).


Request a sample and discover the recent advances in Chronic Obstructive Pulmonary Disease Medication and Chronic Obstructive Pulmonary Disease Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Obstructive Pulmonary Disease Overview

Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Excessive Smoking is the leading risk factor for COPD. In addition, occupational and environmental exposure to chemical fumes, dust, and other lung irritants accounts for 10-20% of cases. People with a history of severe lung infections in childhood are more likely to develop COPD. Also, α1 antitrypsin deficiency is a rare cause of COPD. The most common symptom of COPD is chronic and progressive dyspnea. Production of cough and sputum is present in up to 30% patient population. The symptoms may vary from day to day and may develop airflow limitation by many years. Diagnosis for COPD is primarily clinical. Most of the patients are diagnosed by primary care physicians. Screening is recommended with the occurrence and long-term persistence of symptoms such as chronic cough, excessive sputum production, and dyspnea, especially when these symptoms are accompanied by a history of cigarette smoking or regular exposure to occupational or environmental pollutants or toxins. Spirometry (used to assess the integrated mechanical function of the lung, chest wall, respiratory muscles, and airways) is used to confirm the diagnosis of COPD in suspected cases. Currently, there is no cure for COPD; however, treatment can help slow disease progression rate and symptoms.

Chronic Obstructive Pulmonary Disease Emerging Drugs
• Benralizumab: AstraZeneca
• MV130: Inmunotek S.L.
• SB-240563: GlaxoSmithKline
• SAR440340: Sanofi/Regeneron
• CHF 6001: Chiesi Farmaceutici S.p.A.
• YPL 001: Yungjin Pharm. Co., Ltd.

Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Analysis
There are approx. 70+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

Learn more about the emerging Chronic Obstructive Pulmonary Disease pipeline therapies and Chronic Obstructive Pulmonary Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

DelveInsight's Chronic Obstructive Pulmonary Disease Pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report
• Coverage- Global
• Chronic Obstructive Pulmonary Disease Pipeline Assessment: Product Type, By Stage and Product Type, Route of Administration, By Stage and Route of Administration, By Molecule Type, By Stage and Molecule Type
• Chronic Obstructive Pulmonary Disease Pipeline Companies- GlaxoSmithKline, Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, AstraZeneca, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., CSL Behring; Grifols Biologicals, Novartis, Genentech, Vertex Pharmaceuticals, Glenmark Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Idorsia Pharmaceuticals, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, Boehringer Ingelheim, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Rhizen Pharmaceuticals, Foresee Pharmaceuticals, Brickell Biotech, and others.
• Chronic Obstructive Pulmonary Disease Pipeline Therapies- TD-4208, Tiotr, Itepekimab (SAR440340), Reldesemtiv, Formoterol, Roflumilast, Benralizumab, MV130, SB-240563, SAR440340, CHF 6001, YPL 001, and others.


Table of Content
1. Introduction
2. Executive Summary
3. Chronic Obstructive Pulmonary Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Benralizumab: AstraZeneca
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. YPL 001: Yungjin Pharm. Co., Ltd.
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. CHF6366: Chiesi Farmaceutici
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Chronic Obstructive Pulmonary Disease Key Companies
17. Chronic Obstructive Pulmonary Disease Key Products
18. Chronic Obstructive Pulmonary Disease- Unmet Needs
19. Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
20. Chronic Obstructive Pulmonary Disease- Future Perspectives and Conclusion
21. Chronic Obstructive Pulmonary Disease Analyst Views
22. Chronic Obstructive Pulmonary Disease Key Companies
23. Appendix


Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Chronic Obstructive Pulmonary Disease drugs?
• How many Chronic Obstructive Pulmonary Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Obstructive Pulmonary Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Obstructive Pulmonary Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Obstructive Pulmonary Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Got queries? For more information related to the Chronic Obstructive Pulmonary Disease Pipeline outlook report and Chronic Obstructive Pulmonary Disease Pipeline Drugs @ https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.